keyword
MENU ▼
Read by QxMD icon Read
search

clinical oncology

keyword
https://www.readbyqxmd.com/read/29054815/whole-brain-radiotherapy-or-autologous-stem-cell-transplantation-as-consolidation-strategies-after-high-dose-methotrexate-based-chemoimmunotherapy-in-patients-with-primary-cns-lymphoma-results-of-the-second-randomisation-of-the-international-extranodal-lymphoma
#1
Andrés J M Ferreri, Kate Cwynarski, Elisa Pulczynski, Christopher P Fox, Elisabeth Schorb, Paul La Rosée, Mascha Binder, Alberto Fabbri, Valter Torri, Eleonora Minacapelli, Monica Falautano, Fiorella Ilariucci, Achille Ambrosetti, Alexander Roth, Claire Hemmaway, Peter Johnson, Kim M Linton, Tobias Pukrop, Jette Sønderskov Gørløv, Monica Balzarotti, Georg Hess, Ulrich Keller, Stephan Stilgenbauer, Jens Panse, Alessandra Tucci, Lorella Orsucci, Francesco Pisani, Alessandro Levis, Stefan W Krause, Hans J Schmoll, Bernd Hertenstein, Mathias Rummel, Jeffery Smith, Michael Pfreundschuh, Giuseppina Cabras, Francesco Angrilli, Maurilio Ponzoni, Martina Deckert, Letterio S Politi, Jürgen Finke, Michele Reni, Franco Cavalli, Emanuele Zucca, Gerald Illerhaus
BACKGROUND: The International Extranodal Lymphoma Study Group-32 (IELSG32) trial is an international randomised phase 2 study that addresses two key clinical questions in the treatment of patients with newly diagnosed primary CNS lymphoma. Results of the first randomisation have demonstrated that methotrexate, cytarabine, thiotepa, and rituximab (called the MATRix regimen) is the induction combination associated with significantly better outcome compared with the other induction combinations tested...
October 17, 2017: Lancet Haematology
https://www.readbyqxmd.com/read/29052781/absolute-lymphocyte-counts-at-end-of-induction-correlate-with-distinct-immune-cell-compartments-in-pediatric-b-cell-precursor-acute-lymphoblastic-leukemia
#2
Nina Rolf, Kinga K Smolen, Amina Kariminia, Adam Velenosi, Mario Fidanza, Caron Strahlendorf, Alix E Seif, Gregor S D Reid
Several retrospective studies in children with B cell precursor (BCP) acute lymphoblastic leukemia (ALL) provided clinical evidence that higher absolute lymphocyte counts (ALC) early into treatment significantly correlated with improved relapse-free and overall survival. It still remains unknown, however, whether the predictive role of higher ALCs reflects general bone marrow recovery or a more specific attribute of immune function. To investigate this question, we implemented a prospective observational cohort study in 20 children with BCP ALL on day 29 (D29) of induction chemotherapy and immunophenotyped their lymphoid (T, B and natural killer cells) and myeloid (neutrophils, monocytes, dendritic cells) compartments...
October 20, 2017: Cancer Immunology, Immunotherapy: CII
https://www.readbyqxmd.com/read/29052661/adherence-and-coping-strategies-in-outpatients-with-chronic-myeloid-leukemia-receiving-oral-tyrosine-kinase-inhibitors
#3
Jochen Hefner, Eva-Johanna Csef, Volker Kunzmann
PURPOSE/OBJECTIVES: To assess adherence and coping strategies in outpatients with chronic myeloid leukemia (CML) on oral tyrosine kinase inhibitors (TKIs).
. DESIGN: Prospective, descriptive.
. SETTING: An interdisciplinary oncology outpatient clinic in Germany.
. SAMPLE: 35 outpatients with CML on oral TKIs.
. METHODS: Adherence and coping strategies were assessed with questionnaires. Clinical data were extracted from medical charts...
November 1, 2017: Oncology Nursing Forum
https://www.readbyqxmd.com/read/29052653/distinct-trajectories-of-fatigue-and-sleep-disturbance-in-women-receiving-chemotherapy-for-breast-cancer
#4
Meagan Whisenant, Bob Wong, Sandra A Mitchell, Susan L Beck, Kathi Mooney
PURPOSE/OBJECTIVES: To examine self-reported severity of fatigue and disturbed sleep experienced daily by women with breast cancer during multiple cycles of chemotherapy, exploring potential classes of women experiencing similar symptom trajectories.
. DESIGN: In a secondary analysis, classes of women experiencing similar patterns of fatigue and disturbed sleep were identified.
. SETTING: Oncology clinics in the United States.
. SAMPLE: 166 women with breast cancer receiving chemotherapy...
November 1, 2017: Oncology Nursing Forum
https://www.readbyqxmd.com/read/29052072/long-term-outcomes-of-endoscopic-submucosal-dissection-in-comparison-to-surgery-in-undifferentiated-type-intramucosal-gastric-cancer-using-propensity-score-analysis
#5
Jun Chul Park, Yong Kang Lee, Soon Young Kim, Yunho Roh, Kyu Yeon Hahn, Sung Kwan Shin, Sang Kil Lee, Yong Chan Lee, Hyoung-Il Kim, Jae-Ho Cheong, Woo Jin Hyung, Sung Hoon Noh
BACKGROUND: The treatment of intramucosal early gastric cancer with undifferentiated-type histologies (UD-EGCs) using endoscopic submucosal dissection (ESD) is controversial. This study aimed to compare the clinical and oncologic long-term outcomes of ESD and surgery for UD-EGCs. METHODS: A prospectively collected database of patients who underwent ESD or surgery between January 2006 and December 2012 was established. Patients who diagnosed with UD-EGC and satisfied the expanded indications of ESD were included...
October 19, 2017: Surgical Endoscopy
https://www.readbyqxmd.com/read/29051715/a-multiplex-platform-for-the-identification-of-ovarian-cancer-biomarkers
#6
Kristin L M Boylan, Kate Geschwind, Joseph S Koopmeiners, Melissa A Geller, Timothy K Starr, Amy P N Skubitz
BACKGROUND: Currently, there are no FDA approved screening tools for detecting early stage ovarian cancer in the general population. Development of a biomarker-based assay for early detection would significantly improve the survival of ovarian cancer patients. METHODS: We used a multiplex approach to identify protein biomarkers for detecting early stage ovarian cancer. This new technology (Proseek(®) Multiplex Oncology Plates) can simultaneously measure the expression of 92 proteins in serum based on a proximity extension assay...
2017: Clinical Proteomics
https://www.readbyqxmd.com/read/29050517/the-safety-and-efficacy-of-dabrafenib-and-trametinib-for-the-treatment-of-melanoma
#7
Sarah Knispel, Lisa Zimmer, Theodora Kanaki, Selma Ugurel, Dirk Schadendorf, Elisabeth Livingstone
The introduction of BRAF and MEK inhibitors into clinical practice improved the prognosis of metastatic melanoma patients. The combination of BRAF inhibitor dabrafenib with MEK inhibitor trametinib has shown its superiority to single agent therapy and is characterized by a tolerable spectrum of adverse events which shows a decrease in incidence over time on treatment. Areas covered: The current scientific literature on safety and adverse events (AEs) related to BRAF and MEK-inhibition has been investigated with special focus on the large phase 3 studies (COMBI-v, COMBI-d and CoBRIM) as well as recent updates presented at oncology and melanoma meetings...
October 20, 2017: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/29050499/congenital-factor-deficiencies-in-children-a-report-of-a-single-center-experience
#8
Zafer Şalcıoğlu, Cengiz Bayram, Hülya Şen, Gizem Ersoy, Gönül Aydoğan, Arzu Akçay, Deniz Tuğcu, Ferhan Akıcı, Müge Gökçe, Metin Demirkaya, Ali Ayçiçek, Zafer Başlar
Congenital factor deficiencies (CFDs) refer to inherited deficiency of coagulation factors in the blood. A total of 481 patients with CFDs, who were diagnosed and followed at our Pediatric Hematology and Oncology Clinic between 1990 and 2015, were retrospectively evaluated. Of the 481 cases, 134 (27.8%) were hemophilia A, 38 (7.9%) were hemophilia B, 57 (11.8%) were von Willebrand disease (vWD), and 252 (52.3%) were rare bleeding disorders (RBDs). The median age of the patients at the time of diagnosis and at the time of the study was 4...
January 1, 2017: Clinical and Applied Thrombosis/hemostasis
https://www.readbyqxmd.com/read/29049858/adolescents-and-young-adults-with-brain-tumors-in-the-context-of-molecular-advances-in-neuro-oncology
#9
REVIEW
Michal Zapotocky, Vijay Ramaswamy, Alvaro Lassaletta, Eric Bouffet
Adolescents and young adults (AYA) comprise a specific group of oncology patients with a distinct biological and epidemiological spectrum of central nervous system neoplasms. It has been well documented that they differ clinically, especially in relation to prognosis and chemotherapy tolerance; however, the underlying reasons for this are unclear. Recent advances in the genomics of both childhood and adult brain tumors have provided new explanations and insights into the previously described age-dependent heterogeneity...
October 19, 2017: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/29049611/association-of-a-prophylactic-surgical-approach-to-stage-iv-small-intestinal-neuroendocrine-tumors-with-survival
#10
Kosmas Daskalakis, Andreas Karakatsanis, Ola Hessman, Heather C Stuart, Staffan Welin, Eva Tiensuu Janson, Kjell Öberg, Per Hellman, Olov Norlén, Peter Stålberg
Importance: Primary tumor resection and mesenteric lymph node dissection in asymptomatic patients with stage IV small intestinal neuroendocrine tumors (SI-NETs) are controversial. Objective: To determine the association of locoregional surgery (LRS) performed at diagnosis with outcomes in patients with asymptomatic SI-NETs and distant metastases. Design, Setting, and Participants: This cohort study included asymptomatic patients with stage IV SI-NETs diagnosed from January 1, 1985, through December 31, 2015, and identified using the prospective database of SI-NETs from Uppsala University Hospital, Uppsala, Sweden...
October 19, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/29049434/survival-outcomes-for-patients-with-t3n0m0-squamous-cell-carcinoma-of-the-glottic-larynx
#11
Huaising C Ko, Paul M Harari, Shuai Chen, Aaron M Wieland, Menggang Yu, Andrew M Baschnagel, Randall J Kimple, Matthew E Witek
Importance: Radiotherapy (RT)-based organ preservation approaches for patients with advanced laryngeal cancer have been established stepwise through prospective randomized clinical trials. However, broad adoption of these approaches has stimulated discussion about long-term results challenging their applicability in a heterogeneous patient population, most recently for patients with T3 disease. Objective: To define outcomes in patients with clinical T3N0M0 glottic laryngeal cancer treated with definitive surgical and RT-based approaches...
October 12, 2017: JAMA Otolaryngology—Head & Neck Surgery
https://www.readbyqxmd.com/read/29048993/personalized-risk-prediction-in-clinical-oncology-research-applications-and-practical-issues-using-survival-trees-and-random-forests
#12
Chen Hu, Jon Arni Steingrimsson
A crucial component of making individualized treatment decisions is to accurately predict each patient's disease risk. In clinical oncology, disease risks are often measured through time-to-event data, such as overall survival and progression/recurrence-free survival, and are often subject to censoring. Risk prediction models based on recursive partitioning methods are becoming increasingly popular largely due to their ability to handle nonlinear relationships, higher-order interactions, and/or high-dimensional covariates...
October 19, 2017: Journal of Biopharmaceutical Statistics
https://www.readbyqxmd.com/read/29048388/regulatory-t-cells-and-tumor-associated-macrophages-in-the-tumor-microenvironment-in-non-muscle-invasive-bladder-cancer-treated-with-intravesical-bacille-calmette-gu%C3%A3-rin-a-long-term-follow-up-study-of-a-japanese-cohort
#13
Makito Miyake, Yoshihiro Tatsumi, Daisuke Gotoh, Sayuri Ohnishi, Takuya Owari, Kota Iida, Kenta Ohnishi, Shunta Hori, Yosuke Morizawa, Yoshitaka Itami, Yasushi Nakai, Takeshi Inoue, Satoshi Anai, Kazumasa Torimoto, Katsuya Aoki, Keiji Shimada, Noboru Konishi, Nobumichi Tanaka, Kiyohide Fujimoto
The clinical significance of regulatory T cells (Treg) and tumor-associated macrophages (TAM) in the tumor microenvironment of human bladder cancer remains unclear. The aim of this study is to explore their relevance to oncological features in non-muscle invasive bladder cancer (NMIBC). We carried out immunohistochemical analysis of forkhead box P3 (FOXP3, Treg maker), CD204 (TAM marker), and interleukin-6 (IL6) using surgical specimens obtained from 154 NMIBC patients. The Treg and TAM counts surrounding the cancer lesion and IL6-positive cancer cell counts were evaluated against clinicopathological variables...
October 19, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29047353/precision-medicine-for-all-challenges-and-opportunities-for-a-precision-medicine-approach-to-critical-illness
#14
REVIEW
Christopher W Seymour, Hernando Gomez, Chung-Chou H Chang, Gilles Clermont, John A Kellum, Jason Kennedy, Sachin Yende, Derek C Angus
All of medicine aspires to be precise, where a greater understanding of individual data will lead to personalized treatment and improved outcomes. Prompted by specific examples in oncology, the field of critical care may be tempted to envision that complex, acute syndromes could bend to a similar reductionist philosophy-where single mutations could identify and target our critically ill patients for treatment. However, precision medicine faces many challenges in critical care. These include confusion about terminology, uncertainty about how to divide patients into discrete groups, the challenges of multi-morbidity, scale, and the need for timely interventions...
October 18, 2017: Critical Care: the Official Journal of the Critical Care Forum
https://www.readbyqxmd.com/read/29047203/engineered-cross-reacting-nanobodies-simplify-comparative-oncology-between-humans-and-dogs
#15
E Mazzega, A de Marco
Antibodies cross-reacting with homologue antigens in different species would be essential reagents for the development of comparative oncology studies. In comparison with conventional immunoglobulin Gs, recombinant nanobodies (single-domain variable regions of heavy-chain only antibodies of Camelidae origin) can be easily isolated in vitro and engineered into a variety of reagents with optimized characteristics for different research and clinical applications. We recovered an anti-human epidermal growth factor receptor 2 (anti-HER2) nanobody from a naïve llama library by direct panning on whole cells and expressed it fused to Fc and green fluorescent protein...
October 18, 2017: Veterinary and Comparative Oncology
https://www.readbyqxmd.com/read/29046867/use-of-multicenter-data-in-a-large-cancer-registry-for-evaluation-of-outcome-and-implementation-of-novel-concepts
#16
Gabriele Schubert-Fritschle, Stephanie E Combs, Thomas Kirchner, Volkmar Nüssler, Jutta Engel
Large clinical cancer registries (CCRs) in Germany shall be strengthened by the German Social Code Book V (SGB V) and implemented until the end of 2017. There are currently several large cancer registries that support clinical data for outcome analysis and knowledge acquisition. The various examples of the Munich Cancer Registry outlined in this paper present many-sided possibilities using and analyzing registry data. The main objective of population-based cancer registration within a defined area and the performance of outcomes research is to provide feedback regarding the results to the broad public, the reporting doctors, and the scientific community...
2017: Frontiers in Oncology
https://www.readbyqxmd.com/read/29046165/long-term-use-of-nimotuzumab-in-combination-with-intensity-modulated-radiotherapy-and-chemotherapy-in-the-treatment-of-locoregionally-advanced-nasopharyngeal-carcinoma-experience-of-a-single-institution
#17
Wang Fangzheng, Jiang Chuner, Ye Zhiming, Liu Tongxin, Yan Fengqin, Wang Lei, Li Bin, Hu Fujun, Chen Ming, Qin Weifeng, Fu Zhenfu
In this retrospective review of a single institution's experience, the efficacy and safety of the long-term use of nimotuzumab in combination with intensity-modulated radiotherapy (IMRT) and chemotherapy in the treatment of locally advanced nasopharyngeal carcinoma (NPC) were studied. Between August 2008 and March 2014, 39 newly diagnosed patients with stage III–IV NPC were treated with IMRT, chemotherapy, and nimotuzumab. Twenty patients were diagnosed with stage III (51.3%), 14 with stage IVA (35.9%), and 5 with stage IVB (12...
October 18, 2017: Oncology Research
https://www.readbyqxmd.com/read/29045632/patient-general-practitioner-and-oncologist-views-regarding-long-term-cancer-shared-care
#18
Heike Schütze, Melvin Chin, David Weller, Mark F Harris
Background: The rising incidence of cancer and increasing number of cancer survivors place competing demands on specialist oncology clinics. This has led to a need to consider collaborative care between primary and secondary care for the long-term post-treatment care of cancer survivors. Objective: To explore the views of breast and colorectal cancer survivors, their oncologist and GP about GPs taking a more active role in long-term cancer follow-up care. Methods: Semi-structured interviews using a thematic analysis framework...
October 14, 2017: Family Practice
https://www.readbyqxmd.com/read/29045536/the-warburg-effect-persistence-of-stem-cell-metabolism-in-cancers-as-a-failure-of-differentiation
#19
M Riester, Q Xu, A Moreira, J Zheng, F Michor, R J Downey
BACKGROUND: Two recent observations regarding the Warburg effect are that (i) the metabolism of stem cells is constitutive ('aerobic') glycolysis while normal cellular differentiation involves a transition to oxidative phosphorylation and (ii) the degree of glucose uptake of a malignancy as imaged by 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) is associated with histologic measures of tumor differentiation. Combining these observations, we hypothesized that the high levels of glucose uptake observed in poorly differentiated cancers may reflect persistence of the glycolytic metabolism of stem cells in malignant cells that fail to fully differentiate...
October 13, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29045525/clinical-benefit-of-systemic-treatment-in-patients-with-advanced-pancreatic-and-gastro-intestinal-neuroendocrine-tumours-according-to-esmo-mcbs-and-asco-framework
#20
L D de Hosson, L M van Veenendaal, Y Schuller, W T Zandee, W W de Herder, M E T Tesselaar, H J Klümpen, A M E Walenkamp
BackgroundAssessment of clinical benefit of systemic treatments of rare diseases including gastroenteropancreatic neuroendocrine tumors (GEP-NET) is challenging. Recently several tools have been developed to grade clinical benefit of cancer drugs. European Society for Medical Oncology (ESMO) has developed the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS). The American Society of Clinical Oncology (ASCO) developed and revised the ASCO framework consisting of the Net Health Benefit (NHB) score juxtaposed against the costs of the treatment...
September 26, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
keyword
keyword
85701
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"